{"entity":{"id":"nct00936390","kind":"trial","name":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer","aka":[],"tldr":"A phase 3 trial of Bicalutamide, Flutamide, Goserelin / leuprolide, Buserelin, Triptorelin and Degarelix in Prostate cancer, run by Radiation Therapy Oncology Group, completed.","summary":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer is a phase 3 interventional study registered as NCT00936390 by Radiation Therapy Oncology Group, with 1538 participants recorded, started 2009-09 and reaching its primary completion in 2020-10-03. Interventions recorded: bicalutamide, flutamide, LHRH agonist (antagonist) therapy, Dose-Escalated Radiation Therapy. Conditions recorded: Prostate Cancer.\n\nLinked to the drug Buserelin because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT00936390","url":"https://clinicaltrials.gov/study/NCT00936390"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate","prostate-intermediate-risk"],"sections":[],"technologies":[],"targets":[],"drugs":["bicalutamide","flutamide","goserelin","buserelin","triptorelin","degarelix"],"companies":["nrg-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00936390","phase":"3","setting":"A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer","sponsor":"Radiation Therapy Oncology Group","started":"2009-09","startedType":"actual","yearReported":2022,"enrolled":1538,"enrolledBasis":"registry","outcomes":[{"endpoint":"Percentage of Participants Alive (Overall Survival)","primary":true,"unit":"%","arms":[{"name":"Dose-Escalated Radiation Therapy Alone","n":750,"value":90,"note":"95% CI 87.7 to 92.2; Figures from the ClinicalTrials.gov results section (first posted 2022-10-06), not from a publication"},{"name":"Dose-Escalated Radiation Therapy and Short-Term Androgen-Deprivation","n":742,"value":91,"note":"95% CI 88.8 to 93.1"}],"hr":0.85,"ci":[0.65,1.11],"p":"0.22","source":"https://clinicaltrials.gov/study/NCT00936390?tab=results"}]},"route":"/trials/nct00936390/","neighbours":{"cancer":[{"id":"prostate-intermediate-risk","kind":"cancer","name":"Localised prostate cancer, intermediate risk","route":"/cancers/prostate-intermediate-risk/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"bicalutamide","kind":"drug","name":"Bicalutamide","route":"/drugs/bicalutamide/"},{"id":"buserelin","kind":"drug","name":"Buserelin","route":"/drugs/buserelin/"},{"id":"degarelix","kind":"drug","name":"Degarelix","route":"/drugs/degarelix/"},{"id":"flutamide","kind":"drug","name":"Flutamide","route":"/drugs/flutamide/"},{"id":"goserelin","kind":"drug","name":"Goserelin / leuprolide (ovarian function suppression)","route":"/drugs/goserelin/"},{"id":"triptorelin","kind":"drug","name":"Triptorelin","route":"/drugs/triptorelin/"}],"company":[{"id":"nrg-oncology","kind":"company","name":"NRG Oncology","route":"/companies/nrg-oncology/"}]}}